The role of the GnRH dose and the route of administration on treatment outcome and complications.
A literature review is given on the pulsedose, the pulse interval, the route of administration and the complications of pulsatile GnRH therapy in hypogonadotropic patients. It is concluded that the treatment regimen should be as follows: 1. Start first treatment cycle with a pulsedose of 5 micrograms/pulse and a pulse interval of 120 min. 2. Regardless the outcome of the first treatment cycle, during the second cycle either the dose should be increased to 10 micrograms/pulse or the interval should be reduced to 60 min. 3. Only if insufficient results are obtained with this pulsedose should the dose be increased to a maximum of 20 micrograms/pulse. With respect to the route of administration it is concluded that the choice of the i.v. versus the s.c. route of administration is mainly one of personal preference. Complications are mainly local inflammatory reactions. All other side effects and complications are rare and of minor importance.